Cinarizine - instructions for use, dose, side effects, contraindications

Cinnarizine - a selective blocker of calcium channels, improves cerebral, peripheral and coronary circulation.Inhibits the entry of calcium ions into cells and reduces their content in the depot of the plasmolemma, lowers the tone of the smooth muscles of the arterioles and potentiates the vasodilating effect of carbon dioxide; directly affecting the smooth muscles of blood vessels, reduces the response to biogenic vasoconstrictor substances (epinephrine, norepinephrine, dopamine, angiotensin, vasopressin). It has moderate antihistaminic activity, reduces the excitability of the vestibular apparatus, lowers sympathicotonia. Has a high tropism to the vessels of the brain. In patients with impaired peripheral circulation improves blood supply and potentiates postischemic hyperemia. Increases the ability of erythrocytes to deform and reduces the increased viscosity of the blood. Increases the resistance of muscles to anoxia.

Pharmacokinetics:

The metabolism of Cinnarizine proceeds completely through dealkylation. The process of metabolism begins 30 minutes after ingestion. The drug is resorbed in the stomach and intestines. Cinnarizine reaches peak plasma levels from 1 to 3 hours after administration. The connection of Cinnarizine with plasma proteins is 91%. The half-life is 4 hours.Excreted as metabolites: 1/3 with urine and 2/3 with feces.

Indications:

Ischemic stroke, the period of healing of hemorrhagic stroke and craniocerebral trauma; encephalopathy; labyrinthine disorders (including for maintenance therapy for dizziness, tinnitus, nystagmus, nausea, vomiting of a labyrinthine origin); migraine (prevention of seizures); Meniere's disease; sea and air sickness (prevention); violation of peripheral circulation (prevention and treatment) - obliterating atherosclerosis, obliterating thromboangiitis, Raynaud's disease, diabetic angiopathy, thrombophlebitis, trophic disorders, trophic and varicose ulcers, pre-gangrene conditions, paresthesia, night spasms and cold extremities.

Contraindications:

Hypersensitivity to the drug, pregnancy, breastfeeding.

Carefully:

Parkinson's disease.

Dosing and Administration:

Inside, preferably after a meal.

For violations of cerebral circulation - 25 - 50 mg (1 - 2 tablets) three times a day; when peripheral circulation is disturbed - 50 - 75 mg (2 - 3 tablets) three times a day; with labyrinthine disorders - 25mg three times a day; with sea and air diseases, before the forthcoming trip: adults - 25 mg, if necessary, again after 6 hours.

Children dose reduced by half.

The maximum daily dose should not exceed 225 mg.

With high sensitivity to the drug, treatment starts with 1/2 dose, increasing it gradually. The course of treatment is from several weeks to several months.

Side effects:

Drowsiness, fatigue; headache; extrapyramidal disorders; depression; pain in the epigastric region, dry mouth, indigestion; allergic reactions (skin rash); a decrease in blood pressure; increase in body weight; lupus-like syndrome, lichen planus; sweating; cholestatic jaundice.

Overdose:

Symptoms: vomiting, drowsiness. Tremor, excessive decrease in blood pressure, coma.

The maximum recommended dose should not exceed 225 mg (9 tablets) per day. In case of overdose there is no specific antidote, it is necessary to do a gastric lavage and take Activated carbon. Treatment is symptomatic.

Interaction:

Pharmaceutical: the chemical incompatibility is not known.

Pharmacodynamic: enhances the effects of alcohol, sedatives and antidepressant drugs. At simultaneous application with nootropic, antihypertensive and vasodilating agents strengthens their effect, and with simultaneous application with drugs prescribed for arterial hypotension - reduces their effect.

Pharmacokinetic: no data.

Special instructions:

At the beginning of treatment, it is necessary to refrain from potentially dangerous activities requiring increased attention, and also not to take ethanol. In connection with the presence of antihistamine effect Cinnarizine can affect the result in the anti-doping control of athletes (a false positive result) and can neutralize the positive reactions of skin diagnostic tests (4 days before the study treatment should be canceled).

With prolonged use, it is recommended that a check examination of liver function, kidney function, and peripheral blood picture is recommended. Patients suffering from Parkinson's disease, Cinnarizine should be assigned only in cases where the benefits from his appointment exceed the possible risk of deterioration.

Effect on the ability to drive transp. cf. and fur:At the beginning of treatment, one should refrain from potentially dangerous activities requiring increased attention.

Form release / dosage:

Tablets 25 mg.

Packaging:

10 tablets per contour cell pack.

For 50 tablets in cans of orange glass or cans of polymer.

Storage conditions:

Store in a dry place protected from light.

Keep out of the reach of children.

Shelf life:

2 years. Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N002074 / 01-2003

Date of registration:04.12.2008

The owner of the registration certificate:BIOSINTEZ, PAO BIOSINTEZ, PAO Russia

Manufacturer: & nbsp

BIOSINTEZ, PAO Russia

Information update date: & nbsp09.10.2015

Illustrated instructions

Instructions

Cinnarizine (Cinnarizine)